Login / Signup

A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index.

Tateaki NaitoUchino JunjiToru KojimaYutaka MatanoKoichi MinatoKentaro TanakaTakuro MizukamiShinji AtagiTakashi HigashiguchiKei MuroTakayama KoichiJunji FuruseEiichiro MorishimaToru TakiguchiKazuo Tamura
Published in: Cancer (2022)
Anamorelin is a drug that stimulates appetite and promotes weight gain. This clinical trial was aimed at determining its efficacy and safety in Japanese cancer patients with a low body mass index and cachexia, a syndrome associated with anorexia and weight loss. Anamorelin was found to improve body weight and anorexia-related symptoms in these patients, and these effects were durable for up to 24 weeks. Moreover, anamorelin was generally well tolerated. These findings suggest that anamorelin is a valuable treatment option for patients with cancer cachexia and a low body mass index.
Keyphrases